Alternative Cancer Treatment Market Size, Lucrative Growth, Industry Developments, Market Scope, Industry Insights | Global Cancer Players - Melbourne Integrative Oncology Group, Memorial Sloan Kettering Cancer Center, and The University of Texas MD Ander

Alternative Cancer Treatment Market reached US$ 22.45 billion in 2024 and is expected to reach US$ 49.62 billion by 2033, growing at a CAGR of 9.3% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Alternative Cancer Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

The growing global cancer burden is set to boost the alternative cancer treatment market, with nearly 20 million cases reported in 2022 and projections reaching 24.1 million in 2030 and 29.9 million by 2040 (IARC).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/alternative-cancer-treatment-market?kb

Latest M&A and Strategic Collaborations

Merck KGaA acquired SpringWorks Therapeutics in February 2025 for $3.5 billion to strengthen its rare oncology and targeted cancer drug portfolio. This includes Ogsiveo (nirogacestat) approved for desmoid tumors and late-stage mirdametinib for neurofibromatosis type 1 (NF1).​

Eli Lilly bought Scorpion Therapeutics for up to $2.5 billion, securing rights to STX-478, a PI3Kα inhibitor being developed for breast and advanced solid tumors.​

Bristol Myers Squibb (BMS) subsidiary RayzeBio partnered with Philochem on OncoACP3, a novel radiotheranostic therapy for prostate cancer, valued at $1.3 billion in total milestones.​

Leo Cancer Care raised $40 million in late September 2025 to further alternative radiation delivery systems focusing on patient comfort and adaptive imaging.​

The sustained interest in precision and cell therapies has also seen multiple venture-backed M&A deals across European biotech firms such as Veraxa Biotech merging with Voyager Therapeutics in a $1.6 billion deal for antibody-drug conjugate (ADC) innovation.​

Key Players:

ZEROHARM Sciences, CannaMeds India, Niche Agriculture And Pharmaceuticals Limited. (Kief Wellness), Esperer Nutrition, Jeena Sikho, Carctol, Anatara Medicine, Melbourne Integrative Oncology Group, Memorial Sloan Kettering Cancer Center, and The University of Texas MD Anderson Cancer Center

Growth Forecast Projected:

The Global Alternative Cancer Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Alternative Cancer Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Latest FDA and Regulatory Approvals (2025 Highlights)

Between January and September 2025, over 16 FDA oncology approvals were granted, including several novel and alternative cancer treatments :​

First-in-Class & Alternative Mechanisms

Dordaviprone (Modeyso): Accelerated approval for H3 K27M-mutated diffuse midline glioma (DMG) a breakthrough brain cancer therapy using dual D2/3 receptor and mitochondrial ClpP targeting.​

Zongertinib: First oral tyrosine kinase inhibitor approved for HER2-mutated non-small cell lung cancer (NSCLC).​

Sunvozertinib (Zegfrovy): Received accelerated approval for EGFR exon 20 insertion mutation-positive lung cancer post-chemotherapy.​

Datroway (datopotamab deruxtecan): Approved for unresectable or metastatic HR-positive, HER2-negative breast cancer.​

Keytruda Qlex (pembrolizumab + hyaluronidase alfa-pmph): New subcutaneous formulation offering faster delivery of immunotherapy for multiple cancers.​

Precision and Targeted Approvals

Mirdametinib for NF1-related plexiform neurofibromas (SpringWorks' drug, now part of Merck KGaA portfolio).

Penpulimab-kcqx combination therapy for nasopharyngeal carcinoma (NPC), marking advances in platinum-based chemoimmunotherapy regimens

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=alternative-cancer-treatment-market?kb

Key Segments:

By Treatment Type: (Dietary and Nutritional Supplements, Traditional Medicine, Acupuncture, Mind-Body Therapies, Others)

By Indication: (Breast Cancer, Gynecological Cancers, Lung Cancer, Brain Cancer, Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Alternative Cancer Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Alternative Cancer Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/alternative-cancer-treatment-market?kb

Key News and Breakthrough Research

CAR-NKT Immunotherapy for Solid Tumors: A next-gen CAR-NKT cell therapy demonstrated broad activity against triple-negative breast cancer, with applications in ovarian, lung, and pancreatic cancers. Unlike CAR-T cells, NKT cells can be mass-produced, lowering costs to about $5,000 per dose, and acting as an off-the-shelf platform.​

AI and Neoantigen Vaccines: Alternative therapies such as personalized cancer vaccines and AI-aided neoepitope prediction are accelerating as new clinical trials launch globally in melanoma and cervical cancer.​

MIT Startup unveiled controlled-release cancer tablets that deliver chemotherapeutics steadily and safely through the bloodstream reducing toxicity and improving compliance.​

ImmunityBio continues advancing "living drug" immunotherapies that train the body's immune system to adapt post-treatment, providing quasi-curative potential for bladder and pancreatic cancers.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/alternative-cancer-treatment-market?kb

2025 has been a watershed year for cancer therapy innovation:

$15+ billion in oncology M&A activity (Merck-SpringWorks, Eli Lilly-Scorpion, RayzeBio-Philochem).

First-in-class approvals including DMG-targeted dordaviprone and HER2-mutant zongertinib.

Breakthroughs such as mass-produced CAR-NKT cell immunotherapy, controlled-release drug tablets, and next-gen AI-driven therapeutic vaccines.

With regulators fast-tracking hematologic and rare tumor treatment approvals, global oncology is increasingly shifting towards precision, accessible, and reduced-toxicity cancer management models.

Key details include:

Developed jointly by Russia's National Medical Research Radiology Centre and Engelhardt Institute of Molecular Biology.

Uses an mRNA platform to train the immune system to recognize and destroy cancer cells safely, minimizing side effects compared to chemotherapy or radiation.

Contains four non-harmful viruses designed to activate immune responses focused on tumor destruction.

Initial focus on colorectal cancer treatment, with ongoing development for glioblastoma and melanoma.

Clinical trials with 48 participants demonstrated promising results in tumor size reduction and slowing cancer cell multiplication.

The vaccine rollout is backed by the Russian government, which will provide it free to patients after regulatory approval.

The estimated production cost per dose is about 300,000 rubles ($2,869 USD), covered by government funding.

A personalized nature regulated under a specialized regulatory framework due to its unique, patient-specific approach.

The vaccine is expected to launch beginning in 2025, with human trials initiated as early as September-October 2025.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.